Search hospitals > Illinois > Alton
Alton Memorial Hospital
Claim this profileAlton, Illinois 62002
Conducts research for Prostate Adenocarcinoma
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
Conducts research for Breast Cancer
Conducts research for Small Cell Lung Cancer
8 reported clinical trials
6 medical researchers
Summary
Alton Memorial Hospital is a medical facility located in Alton, Illinois. This center is recognized for care of Prostate Adenocarcinoma, Prostate Cancer, Lung Cancer, Breast Cancer, Small Cell Lung Cancer and other specialties. Alton Memorial Hospital is involved with conducting 8 clinical trials across 24 conditions. There are 6 research doctors associated with this hospital, such as Jiayi Huang, M.D., Hiram A Gay, M.D., Brian C Baumann, and Pamela Samson, M.D., MPHS.Top PIs
Jiayi Huang, M.D.Washington University School of Medicine3 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
19 reported clinical trials
35 drugs studied
Hiram A Gay, M.D.Washington University School of Medicine6 years of reported clinical research
Studies Prostate Cancer
Studies Squamous Cell Carcinoma
15 reported clinical trials
31 drugs studied
Brian C BaumannWashington University School of Medicine6 years of reported clinical research
Studies Prostate Cancer
Studies Bladder Cancer
15 reported clinical trials
52 drugs studied
Pamela Samson, M.D., MPHSWashington University School of Medicine6 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
30 drugs studied
Clinical Trials running at Alton Memorial Hospital
Prostate Cancer
Skin Cancer
Lung Cancer
Prostate Adenocarcinoma
Esophageal Carcinoma
Small Cell Lung Cancer
Kidney Cancer
Breast Cancer
Eyelid Cancer
Esophageal cancer
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Shorter vs Usual Radiation Therapy
for Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Recruiting2 awards Phase 310 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Alton Memorial Hospital?
Alton Memorial Hospital is a medical facility located in Alton, Illinois. This center is recognized for care of Prostate Adenocarcinoma, Prostate Cancer, Lung Cancer, Breast Cancer, Small Cell Lung Cancer and other specialties. Alton Memorial Hospital is involved with conducting 8 clinical trials across 24 conditions. There are 6 research doctors associated with this hospital, such as Jiayi Huang, M.D., Hiram A Gay, M.D., Brian C Baumann, and Pamela Samson, M.D., MPHS.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.